Orphan drug expenditures in the United States: A historical and prospective analysis, 2007-18

Health Affairs

Volumn 35, Issue 9, 2016, Pages 1588-1594

  Divino, Victoria ^a   DeKoven, Mitch ^a   Kleinrock, Michael ^b   Wade, Rolin L ^a   Kaura, Satyin ^c  

^a IQVIA   (United States)

^b IMS Institute for Healthcare Informatics   (United States)

^c CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG; DRUG;

ARTICLE; BUDGET; DATA BASE; DRUG COST; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HISTORICAL RESEARCH; TREND STUDY; UNITED STATES; DRUG APPROVAL; DRUG MANUFACTURE; ECONOMICS; FACTUAL DATABASE; FEMALE; HEALTH CARE COST; HUMAN; LEGISLATION AND JURISPRUDENCE; MALE; PROSPECTIVE STUDY; RISK ASSESSMENT;

DATABASES, FACTUAL; DRUG APPROVAL; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; ORPHAN DRUG PRODUCTION; PHARMACEUTICAL PREPARATIONS; PROSPECTIVE STUDIES; RISK ASSESSMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84988420038     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2016.0030     Document Type: Article

References (33)

1. Food and Drug Administration. Developing products for rare diseases and conditions [Internet]. Silver Spring (MD): FDA; [last updated 2016 Mar 30; cited 2016 Jul 20]. Available from: http://www.fda.gov/ forindustry/DevelopingProductsfor rareDiseasesConditions/default.htm
2. Braun MM, Farag-El-Massah S, Xu K, Coté TR. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov. 2010; 9(7):519-22.
3. Food and Drug Administration. Search orphan drug designations and approvals [Internet]. Silver Spring (MD): FDA; [cited 2016 Jul 20]. Available from: http://www.accessdata.fda.gov/scripts/ opdlisting/oopd/
4. Handfield R, Feldstein J. Insurance companies' perspectives on the orphan drug pipeline. Am Health Drug Benefits. 2013;6(9):589-98.
5. Peabody JW, Ruby A, Cannon P. The economics of orphan drug policy in the US. Can the legislation be improved? Pharmacoeconomics. 1995;8(5):374-84.
6. Wellman-Labadie O, Zhou Y. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy. 2010; 95(2-3):216-28.
7. Cohen JP, Felix A. Are payers treating orphan drugs differently? J Mark Access Health Policy. 2014;2:23513.
8. Hyde R, Dobrovolny D. Orphan drug pricing and payer management in the United States: are we approaching the tipping point? Am Health Drug Benefits. 2010;3(1):15-23.
9. Robinson SW, Brantley K, Liow C, Teagarden JR. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans. J Manag Care Spec Pharm. 2014;20(10):997-1004.
10. Hutchings A, Schey C, Dutton R, Achana F, Antonov K. Estimating the budget impact of orphan drugs in Sweden and France 2013-2020. Orphanet J Rare Dis. 2014;9:22.
11. Kanters TA, Steenhoek A, Hakkaart L. Orphan drugs expenditure in the Netherlands in the period 2006-2012. Orphanet J Rare Dis. 2014; 9:154.
12. Orofino J, Soto J, Casado MA, Oyagüez I. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007. Appl Health Econ Health Policy. 2010;8(5):301-15.
13. Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010-2020. Orphanet J Rare Dis. 2011; 6:62.
14. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. J Med Econ. 2010;13(2):295-301.
15. Food and Drug Administration. Designating an orphan product: drug and biological products: frequently asked questions (FAQ) [Internet]. Silver Spring (MD): FDA; [last updated 2015 Oct 27; cited 2016 Jul 20]. Available from: http:// www.fda.gov/ForIndustry/ DevelopingProductsforRare DiseasesConditions/Howtoapplyfor OrphanProductDesignation/ ucm240819.htm
16. Food and Drug Administration. Drugs@FDA [Internet]. Silver Spring (MD): FDA; [cited 2016 Jul 20]. Available from: http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm?fuseaction= Search.Search_Drug_Name
17. IMS Health. IMS MIDAS: global analysis made easy [Internet]. London: IMS Health; c 2012 [cited 2016 Jul 20]. Available from: https:// www.imshealth.com/files/web/ Global/Market%20Insights/MIDAS %20Slim%20Jim%20BrEv%20 0113_spread_final.pdf
18. Cowen and Company. Therapeutic categories outlook. New York (NY): Cowen and Company; 2014 Mar.
19. IMS Health. Market Prognosis 2014-2018, USA. London: IMS Health; 2014 Sep 30.
20. IMS Health. IMS market prognosis: the authority in predicting future pharmaceutical market trends [Internet]. London: IMS Health; c 2014 [cited 2016 Jul 20]. Available from: https://www.imshealth.com/files/ web/Global/Market%20Insights/ Market_Prognosis_the_authority_ link.pdf
21. Food and Drug Administration. Facts about generic drugs [Internet]. Silver Spring (MD): FDA; [last updated 2016 Jun 28; cited 2016 Jul 21]. Available from: http://www.fda.gov/drugs/resourcesforyou/ consumers/buyingusingmedicine safely/understandinggenericdrugs/ ucm167991.htm
22. Needleman K. Rare diseases and FDA: perspectives from the Office of Orphan Products Development (OOPD) [Internet]. Presentation at: 1st IRDiRC Conference; 2013 Apr 16-17; Dublin [cited 2016 Jul 21]. Available from: http://www.irdirc.org/wp-content/uploads/2013/06/ Katherine-Needleman.pdf
23. Reese JH. FDA orphan drug designation 101 [Internet]. Presentation at: Worldwide Orphan Medicinal Designation Workshop; 2014 Mar 10; London [cited 2016 Jul 21]. Available from: http://www.ema.europa.eu/docs/en_GB/document_ library/Presentation/2014/03/ WC500164160.pdf
24. IMS Institute for Healthcare Informatics. Innovation in cancer care and implications for health systems: global oncology trend report. Parsippany (NJ): IMS Institute for Healthcare Informatics; 2014 May.
25. Hartman M, Martin AB, Lassman D, Catlin A, National Health Expenditure Accounts Team. National health spending in 2013: growth slows, remains in step with the overall economy. Health Aff (Millwood). 2015; 34(1):150-60.
26. IMS Institute for Healthcare Informatics. Medicine use and shifting costs of healthcare: a review of the use of medicines in the U.S. in 2013. Parsippany (NJ): IMS Institute for Healthcare Informatics; 2014 Apr.
27. Miller KL, Lanthier M. Trends in orphan new molecular entities, 1983-2014: half were first in class, and rare cancers were the most frequent target. Health Aff (Millwood). 2016;35(3):464-70.
28. Lichtenberg FR. The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999-2007. Eur J Health Econ. 2013;14(1): 41-56.
29. Hyry HI, Stern AD, Cox TM, Roos JC. Limits on use of health economic assessments for rare diseases. QJM. 2014;107(3):241-5.
30. Dragojlovic N, Rizzardo S, Bansback N, Mitton C, Marra CA, Lynd LD. Challenges in measuring the societal value of orphan drugs: insights from a Canadian stated preference survey. Patient. 2015;8(1):93-101.
31. Desser AS, Gyrd-Hansen D, Olsen JA, Grepperud S, Kristiansen IS. Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67. BMJ. 2010;341:c4715.
32. Orphanet. Lists of medicinal products for rare diseases in Europe [Internet]. Paris: Orphanet; 2016 Jul [cited 2016 Jul 26]. (Orphanet Report Series). Available from: http:// www.orpha.net/orphacom/cahiers/ docs/GB/list_of_orphan_drugs_in_ europe.pdf
33. Hall AK, Carlson MR. The current status of orphan drug development in Europe and the US. Intractable Rare Dis Res. 2014;3(1):1-7.